Tenaya Therapeutics (TNYA) EBITDA (2020 - 2026)

Tenaya Therapeutics has reported EBITDA for 7 years, with the latest figure at -$44.1 million in Q2 2026.

• On a quarterly basis, EBITDA fell 83.07% year-over-year to -$44.1 million in Q2 2026; TTM through Jun 2026 was -$105.9 million, a 2.8% decrease from a year earlier, with the FY2025 full-year figure at -$93.3 million, up 19.51% from the prior year.
• EBITDA was -$44.1 million for Q2 2026 at Tenaya Therapeutics, down from -$20.1 million in the prior quarter.
• The five-year high for EBITDA was -$20.1 million in Q1 2026, with the low at -$44.1 million in Q2 2026.
• Average EBITDA over 5 years is -$29.5 million, with a median of -$30.9 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2026: EBITDA sank 137.73% in 2022, then gained 27.14% in 2026.
• Over 5 years, EBITDA stood at -$34.6 million in 2022, then increased by 8.98% to -$31.4 million in 2023, then increased by 21.61% to -$24.7 million in 2024, then gained by 15.73% to -$20.8 million in 2025, then plunged by 112.22% to -$44.1 million in 2026.
• The last three EBITDA figures came in at -$44.1 million (Q2 2026), -$20.1 million (Q1 2026), and -$20.8 million (Q4 2025), per Business Quant data.